See Every Facet of the Story.
Published loading...Updated

Whole-body PET/CT predicts response to HER2-targeted therapy in metastatic breast cancer patients

Summary by Medical Xpress
A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to human epidermal growth factor receptor 2 (HER2)-targeted treatment in HER2-positive metastatic breast cancer patients, according to new research published in the Journal of Nuclear Medicine. By providing whole-body quantification of HER2 expression, 68Ga-ABY-025 PET/CT can play a valuable role in treatment planning and could spare patients from unnecessary drug-related si…

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Medical Xpress broke the news in on Wednesday, September 27, 2023.
Sources are mostly out of (0)